SCHEMBL2961764

SCHEMBL2961764

O=C(O)c1cc(F)cc2oc(-c3ccccc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.49
DHODH Q02127 5/20 0.47
TOP2A P11388 1/20 0.47
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HIF1A Q16665 1/20 0.46
KDM4E B2RXH2 4/20 0.45
NPC1 O15118 3/20 0.45
HDAC6 Q9UBN7 1/20 0.43
ALDH1A1 P00352 2/20 0.42
POLB P06746 2/20 0.42
CASP3 P42574 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2954884 0.84 ESR2 (0.50) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL2954385 0.84 RCE1 (0.50) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL2954868 0.84 RAB9A (0.54) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL2959750 0.82 DHODH (0.51) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL2964178 0.79 GPR35 (0.48) DHODHTOP2ARAB9AKDM4ENPC1
SCHEMBL2957123 0.79 TOP2A (0.53) RCE1TOP2ARAB9ASMN1; SMN2HIF1A
SCHEMBL121325 0.78 TOP2A (0.65) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL442954 0.78 DHODH (0.49) RCE1DHODHTOP2ARAB9ASMN1; SMN2
SCHEMBL1005909 0.77 KEAP1 (0.42) DHODHRAB9AKDM4ENPC1ALDH1A1
SCHEMBL121392 0.77 HTR3A (0.54) DHODHTOP2ARAB9AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781430-B2 Benzoxazole carboxamides for treating CINV and IBS-D ALBANY MOLECULAR RESEARCH, INC. (US) 2010-08-24 US disclosed
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2008-05-08 US disclosed
US-7307094-B2 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2007-12-11 US disclosed
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D HTR3E, BRS3, HTR3A RCE1 816/4885DHODH 2821/4885TOP2A 1421/4885
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D HTR3E, BRS3, HTR3A RCE1 816/4885DHODH 2821/4885TOP2A 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.